Navigation Links
GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
Date:6/16/2008

spectrum of bacterial susceptibility. I look forward to having a great synergy in this important and strategic collaboration."

Bacterial efflux pumps are an intrinsic defense mechanism in gram-negative bacteria that expel toxins such as antibiotics that have permeated the outer cell membrane before they can reach their targets and kill the bacteria. Higher intracellular antibiotic concentrations achieved through efflux pump inhibition can increase the potency and pharmacological barrier against other drug resistance mechanisms (e.g., target-based mutations). There are currently no drugs approved to inhibit the activity of these efflux pumps and restore the potency of otherwise effective antibiotics. Mpex has been a leader in this field of research for a number of years and has identified several series of lead EPIs that are now being optimized for development. These compounds have been shown in both in vitro and in vivo pre-clinical studies to significantly improve the potency of a number of different antibiotic classes against drug- resistant gram-negative pathogens, including Pseudomonas aeruginosa and Klebsiella pneumoniae.

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's lead product candidate, MP-376, is a proprietary aerosol formulation of levofloxacin that is being developed clinically as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis and severe chronic bronchitis. The company has also built a discovery and development platform and intellectual property estate arou
'/>"/>

SOURCE Mpex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
2. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
3. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
4. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
7. Vaccinex Antibody Licensed to GlaxoSmithKline
8. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
9. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
10. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
11. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
... from Phase II Study Shows 71% Objective Tumor Response Rate ... , - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median ... , ORLANDO, Fla. and TUSTIN, Calif., June 1 Peregrine ... preliminary results from a Phase II trial of its lead ...
... UCB, Inc. and the Crohn,s Disease Working Group (CDWG) today ... Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each ... or basic research, totaling $175,000 for all four grants. The ... awards were funded by a grant from UCB. A ...
... Therapeutics announced today that promising results from ongoing clinical studies ... presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 ... 2, in Orlando, Florida. , , (Logo: ... , , "We are delighted with the depth ...
Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5
(Date:7/10/2014)... Institute for Basic Science (IBS), the main organization of ... Korea, has announced that a group of researchers, led ... technology in the field of optogenetics that can remotely ... new technology "OptoTrk" and it has succeeded with neuronal ... technology is that it requires only light to activate ...
(Date:7/10/2014)... soap might not be ape friendly, and the situation appears ... the Cell Press journal Current Biology on July ... led to the conversion of Southeast Asian forest into oil ... are not put in place very soon, researchers say the ... will be bad news for great apes there as well. ...
(Date:7/10/2014)... Imagine the open ocean as a microbial megacity, teeming ... drop of water, hundreds of types of bacteria can ... of these ocean microbes have their own daily cyclesnot ... to wake up, commute, work, and eat at the ... sun. Light-loving photoautotrophsbacteria that need solar energy to help ...
Breaking Biology News(10 mins):New optogenetic tool for controlling neuronal signalling by blue light 2Hunger for vegetable oil means trouble for Africa's great apes 2New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3
... Pop Quiz: what creatures make up more than 70% ... and have long served as model organisms in many ... To begin exploring this question, a new ... was formed and held its inaugural workshop at Nova ...
... are sensitive to social influences but they maintain their ... to what the majority of group members are doing. ... obtain greater rewards, MPI researchers found. ... a rich palette of learning behaviour, both individually and ...
... (UH) Case Medical Center Seidman Cancer Center and Case ... how changes in the genetic composition of breast cancer ... chemotherapy can predict future clinical outcomes in patients. ... reduction in the most commonly mutated genes in breast ...
Cached Biology News:New organization brings together top researchers to sequence genomes of invertebrates 2New organization brings together top researchers to sequence genomes of invertebrates 3Chimpanzees are rational, not conformists 2Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy 2
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: